Severity assessment of skin and soft tissue infections: Cohort study of management and outcomes for hospitalized patients

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 2, 2011, Pages 387-397

  Marwick, Charis ^a   Broomhall, Janice ^a   McCowan, Colin ^a   Phillips, Gabby ^b   Gonzalez McQuire, Sebastian ^c,e   Akhras, Kasem ^d,f   Merchant, Sanjay ^d   Nathwani, Dilip ^b   Davey, Peter ^a  

^a Division of Clinical and Population Sciences and Education   (United Kingdom)

^b NINEWELLS HOSPITAL   (United Kingdom)

^c Janssen Animal Health   (United Kingdom)

^d JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^e GLAXOSMITHKLINE   (United Kingdom)

^f Pfizer Ltd   (United States)

Author keywords

Cellulitis; MRSA; Sepsis; SSTIs; Staphylococcal infections; Staphylococcus aureus

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFALEXIN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; ERYTHROMYCIN; FLUCLOXACILLIN; FUSIDIC ACID; GENTAMICIN; LEVOFLOXACIN; METRONIDAZOLE; NORFLOXACIN; PENICILLIN G; PENICILLIN V; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; TRIMETHOPRIM; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; COMORBIDITY; DISEASE SEVERITY; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRACTICE GUIDELINE; SCORING SYSTEM; SEPSIS; SKIN INFECTION; SOFT TISSUE INFECTION; STANDARDIZED EARLY WARNING SCORE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COHORT STUDIES; FEMALE; HOSPITALIZATION; HUMANS; INFLAMMATION; MALE; METHICILLIN RESISTANCE; MIDDLE AGED; SCOTLAND; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 78651425827     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq362     Document Type: Article

References (33)

1. Ki V, Rotstein C. Bacterial skin and soft tissue infections in adults: a review of their epidemiology, pathogenesis, diagnosis, treatment and site of care. Can J Infect Dis Med Microbiol 2008; 19: 173-84.
2. Stevens DL, Bisno AL, Chambers HF et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41: 1373-406.
3. Ansari F, Erntell M, Goossens H et al. The European surveillance of antimicrobial consumption (ESAC) point-prevalence survey of antibacterial use in 20 European hospitals in 2006. Clin Infect Dis 2009; 49: 1496-504.
4. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. New Engl J Med 1997; 336: 243-50.
5. CREST (Clinical Resource Efficiency Support Team). CREST (Clinical Resource Efficiency Support Team) Guidelines On The Management Of Cellulitis In Adults. In: CREST, ed: DHSS Northern Ireland, 2005; 1-31.
6. Morris A. Cellulitis and erysipelas. BMJ Clin Evid 2003; 12: 1708.
7. Bosshardt TL, Henderson VJ, Organ CH Jr. Necrotizing soft-tissue infections. Arch Surg 1996; 131: 846-52; discussion, 852-4.
8. Elliott DC, Kufera JA, Myers RA. Necrotizing soft tissue infections. Risk factors for mortality and strategies for management. Ann Surg 1996; 224: 672-83.
9. Eriksson B, Jorup-Ronstrom C, Karkkonen K et al. Erysipelas: clinical and bacteriologic spectrum and serological aspects. Clin Infect Dis 1996; 23: 1091-8.
10. Wall DB, de Virgilio C, Black S et al. Objective criteria may assist in distinguishing necrotizing fasciitis from nonnecrotizing soft tissue infection. Am J Surg 2000; 179: 17-21.
11. Wong CH, Khin LW, Heng KS et al. The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med 2004; 32: 1535-41.
12. Edelsberg J, Berger A, Weber DJ et al. Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections. Infect Control Hosp Epidemiol 2008; 29: 160-9.
13. Eron LJ, Lipsky BA, Low DE et al. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother 2003; 52 Suppl 1: i3-17.
14. Jones GR. A re-evaluation of blood cultures. Rev Med Microbiol 1995; 6: 109-18.
15. Jones GR, Lowes JA. The systemic inflammatory response as a predictor of bacteraemia and outcome from sepsis. Q J Med 1996; 89: 515-22.
16. Charlson ME, Pompei P, Ales KL. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
17. Bone RC, Balk RA, Cerra FB et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-55.
18. Paterson R, MacLeod DC, Thetford D et al. Prediction of in-hospital mortality and length of stay using an early warning scoring system: clinical audit. Clin Med 2006; 6: 281-4.
19. Marwick C, Watts E, Evans J et al. Quality of care in sepsis management: development and testing of measures for improvement. J Antimicrob Chemother 2007; 60: 694-7.
20. Jorup-Ronstrom C, Britton S, Gavlevik A et al. The course, costs and complications of oral versus intravenous penicillin therapy of erysipelas. Infection 1984; 12: 390-4.
21. Gao F, Melody T, Daniels DF et al. The impact of compliance with the 6-hour and 24-hour sepsis bundles on hospital mortality in patients with severe sepsis: a prospective observational study. Crit Care 2005; 9: 764-70.
22. Levy MM, Fink MP, Marshall JC et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003; 29: 530-8.
23. Cuthbertson BH, Boroujerdi M, Prescott G. The use of combined physiological parameters in the early recognition of the deteriorating acute medical patient. J R Coll Physicians Edinb 2010; 40: 19-25.
24. Ammerlaan H, Seifert H, Harbarth S et al. Adequacy of antimicrobial treatment and outcome of Staphylococcus aureus bacteremia in 9 Western European countries. Clin Infect Dis 2009; 49: 997-1005.
25. Schwaber MJ, Carmeli Y. The effect of antimicrobial resistance on patient outcomes: importance of proper evaluation of appropriate therapy. Critical Care 2009; 13: 106-7.
26. Furuno JP, McGregor JC, Harris AD et al. Identifying groups at high risk for carriage of antibiotic-resistant bacteria. Arch Intern Med 2006; 166: 580-5.
27. Lodise TP, McKinnon PS, Rybak M. Prediction model to identify patients with Staphylococcus aureus bacteremia at risk for methicillin resistance. Infect Control Hosp Epidemiol 2003; 24: 655-61.
28. Sax H, Harbrath S, Gavazzi G et al. Prevalence and prediction of previously unknown MRSA carriage on admission to a geriatric hospital. Age Ageing 2005; 34: 456-62.
29. Nathwani D. New antibiotics for the management of complicated skin and soft tissue infections: are they any better?. Int J Antimicrob Agents 2009; 34 Suppl 1: S24-9.
30. Stevens DL. Antimicrobial agents for complicated skin and skinstructure infections: noninferiority margins, placebo-controlled trials, and the complexity of clinical trials. Clin Infect Dis 2009; 49: 392-4.
31. Kumar A, Roberts D, Wood KE et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-96.
32. Spellberg B, Talbot GH, Boucher HW et al. Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials. Clin Infect Dis 2009; 49: 383-91.
33. García MS. Early antibiotic treatment failure. Int J Antimicrob Agents 2009; 34: S14-9.